mAbxience and Egis Enter Strategic License Agreement for Biosimilar Candidates in Key Central and Eastern European MarketsMiguel Martínez-Cava2024-11-12T08:59:05+01:00November 12, 2024|Press releases|
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar CandidateMiguel Martínez-Cava2024-10-03T14:33:04+02:00October 3, 2024|Press releases|
mAbxience Appoints Jurgen Van Broeck as New CEOMiguel Martínez-Cava2024-05-09T09:42:26+02:00May 9, 2024|Press releases|
Europe’s biosimilar blind spot: many biologics losing exclusivity have no competitionadriana.polo2025-04-23T15:36:21+02:00April 23, 2025|News|
Regulations, market shifts and the biosimilar void: what’s at stake?adriana.polo2025-04-23T15:36:58+02:00March 28, 2025|News|
Why are biosimilars still met with hesitation—and how can we change that?adriana.polo2025-03-25T10:43:27+01:00March 25, 2025|News|
